DWTX: Interim Data for Phase 2b Trial in 4Q25
On March 31, 2025, Dogwood Therapeutics, Inc. announced financial results for 2024 and provided a business update. The company recently dosed the...
387 Views
DWTX: First Patient Dosed in Phase 2b Trial of Halneuron in CINP Debt Conversion Strengthens Balance Sheet
On March 18, 2025, Dogwood Therapeutics, Inc. announced that the first patient was dosed in the Phase 2b HALT-CINP clinical trial of its lead...
231 Views
DWTX: Phase 2 Long COVID Results Expected Soon
On November 7, 2024, Dogwood Therapeutics, Inc. (DWTX) announced financial results for the third quarter of 2024 and provided a business...
230 Views
Dogwood Therapeutics, Inc. - DWTX: Virios Therapeutics Becomes Dogwood Therapeutics
On October 7, 2024, Virios Therapeutics, Inc. (VIRI) announced a business combination with privately-held Wex Pharmaceuticals, Inc. to form Dogwood...
384 Views
VIRI: Enrollment Complete in Phase 2a Long COVID Trial Results Expected in October 2024
On August 8, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the second quarter of 2024 and provided a business update. The...
287 Views